Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
DEEP READ
Munambam Waqf issue decoded
access_time 16 Nov 2024 10:48 PM IST
Ukraine
access_time 16 Aug 2023 11:16 AM IST
Foreign espionage in the UK
access_time 22 Oct 2024 2:08 PM IST
Netanyahu: the world’s Number 1 terrorist
access_time 5 Oct 2024 11:31 AM IST
exit_to_app
Homechevron_rightLifestylechevron_rightHealthchevron_rightDCGI grants emergency...

DCGI grants emergency use permission to single-dose Sputnik Light Covid vaccine

text_fields
bookmark_border
DCGI grants emergency use permission to single-dose Sputnik Light Covid vaccine
cancel

New Delhi: The Drugs Controller General of India has granted emergency use permission to single-dose Sputnik Light Covid vaccine in the country, Union Health Minister Mansukh Mandaviya said on Sunday.

This comes following recommendations of an expert panel of India's central drug authority to grant restricted emergency use authorisation to Sputnik Light subject to various regulatory provisions.

Sputnik-Light is the same as component-1 of Sputnik V.

"DCGI has granted emergency use permission to single-dose Sputnik Light COVID-19 vaccine in India. This is the ninth COVID-19 vaccine in the country. This will further strengthen the nation's collective fight against the pandemic," Mandaviya tweeted.

An official source said in light of recommendations of Subject Expert Committee (SEC) following a meeting on January 31, Dr Reddy's Laboratories presented its proposal for grant of permission to import Sputnik Light for restricted emergency use and booster dose vaccination along with analysis of safety and efficacy data including its benefit against Omicron.

The firm presented that Sputnik Light vaccine is approved in 29 countries, including Russia and Argentina.

"The SEC on COVID-19 of the CDSCO, which deliberated on the application by Dr Reddy's Laboratories, noted the safety and immunogenicity data presented by the firm from the Indian study is comparable with that of the ongoing Phase-3 clinical trial interim data from Russia," the source said.

The interim data of efficacy trial from Russia has shown 65.4 percent efficacy, 21 days after immunization.

"After detailed deliberation, the SEC had recommended grant of permission for restricted use in an emergency situation subject to various regulatory provisions including," the source said.

Show Full Article
TAGS:Covid UpdatesDCGISputnik Light
Next Story